Phase 4 Multiple Sclerosis Trial, Recruiting NCT06136728 Sponsor: MGH Institute of Health Professions Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 4 Multiple Sclerosis Trial, Recruiting

NCT06136728
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a confirmed diagnosis of multiple sclerosis (MS)
  • People whose level of physical disability is rated at 6.5 or below on a standard MS disability scale (called the EDSS)
  • People who can walk 25 feet in between 6 and 45 seconds (based on an average of two attempts)
  • People who can stand without support for at least 10 seconds
  • People who score 23 or higher on a standard memory and thinking assessment (called the Montreal Cognitive Assessment)
  • People who have not had an MS relapse (flare-up) in the past 3 months
  • People who are not currently taking a medication called dalfampridine, or who have never taken it and stopped because of side effects
  • People who are not currently receiving physical therapy

Who may not be able to join:

  • People who have another neurological condition or a bone or joint problem that affects how they move or are physically active
  • People who are unable to follow a 3-step spoken instruction given in English
  • People who have been hospitalised for any reason in the past 3 months
  • People who have high blood pressure or diabetes that is not well controlled
  • People who have a history of seizures
  • People who have reduced kidney function
  • Women who are pregnant, breastfeeding, or trying to become pregnant
  • People who cannot have an MRI scan — though the trial site may still allow participation in other parts of the study if all other criteria are met (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Prudence Plummer, PhD, PT, MGH Institute of Health Professions

Phone: 617-724-3103

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
MGH Institute of Health Professions
Registry
ClinicalTrials.gov
Start date
12 June 2024
Est. completion
1 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Timed 25-Foot Walk (T25FW)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov